---
title: "Jefferies Remains a Buy on C4 Therapeutics (CCCC)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282349247.md"
description: "In a report released today, from Jefferies maintained a Buy rating on C4 Therapeutics, with a price target of $14.00.Easter Sale - 70% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks C4 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.50."
datetime: "2026-04-10T12:56:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282349247.md)
  - [en](https://longbridge.com/en/news/282349247.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282349247.md)
---

# Jefferies Remains a Buy on C4 Therapeutics (CCCC)

In a report released today, from Jefferies maintained a Buy rating on C4 Therapeutics, with a price target of $14.00.

### Easter Sale - 70% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

C4 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.50.

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [CCCC.US](https://longbridge.com/en/quote/CCCC.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)